Co‐vaccination with adeno‐associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM‐CSF can elicit strong and prolonged neutralizing antibody
Authors:
Open Access
- 25 August 2004
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 113 (1) , 93-100
Abstract
Non‐infectious human papillomavirus‐like particles (VLPs), encoded by the major capsid gene L1, have been shown to be effective as vaccines to prevent cervical cancer. We have developed the genetic immunization of the L1 gene to induce a neutralizing antibody. We constructed and generated a recombinant adeno‐associated virus encoding human papillomavirus (HPV) 16 L1 protein that could form virus‐like particles in transduced cells. Previous reports have demonstrated that the formation of VLP is necessary to induce high titers of neutralizing antibodies to protect an animal from viral challenge. Therefore, we carried out a single intramuscular (i.m.) injection with recombinant adeno‐associated virus encoding HPV‐16 L1 protein (rAAV‐16L1) in BALB/c mice, which ultimately produced stronger and more prolonged neutralizing L1 antibodies, when compared to the DNA vaccine. Immunohistochemistry showed that the accumulation of antigen presenting cells, such as macrophages and dendritic cells, in rAAV‐16L1 and L1 DNA‐injected muscle fibers may be due to the L1 protein expression, but not to AAV infection. When compared to the L1 VLP vaccine, however, the titers of neutralizing L1 antibodies induced by VLP were higher than those induced by rAAV‐16L1. Co‐vaccinating with rAAV‐16L1 and adenovirus encoding murine GM‐CSF (rAAV‐16L1/rAd‐mGM‐CSF) induced comparable higher levels of neutralizing L1 antibodies with those of VLP. This implies that a single i.m. co‐injection with rAAV‐16L1/rAd‐mGM‐CSF can achieve the same vaccine effect as a VLP vaccine requiring 3 booster injections.Keywords
This publication has 75 references indexed in Scilit:
- Combination of adeno-associated virus and adenovirus vectors expressing bone morphogenetic protein-2 produces enhanced osteogenic activity in immunocompetent ratsBiochemical and Biophysical Research Communications, 2004
- An Oral Vaccine Against NMDAR1 with Efficacy in Experimental Stroke and EpilepsyScience, 2000
- The Expression of Type I Growth Factor Receptors in the Squamous Neoplastic Changes of Uterine CervixGynecologic Oncology, 1999
- Adeno-Associated Virus-Mediated Gene Transfer to the Brain: Duration and Modulation of ExpressionHuman Gene Therapy, 1999
- rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophyGene Therapy, 1999
- Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvantEuropean Journal of Clinical Microbiology & Infectious Diseases, 1994
- Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.Journal of Experimental Medicine, 1992
- GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cellsNature, 1992
- Baculovirus Expression of the Human Papillomavirus Type 16 Capsid Proteins: Detection of L1-L2 Protein ComplexesJournal of General Virology, 1991
- Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells.Journal of Experimental Medicine, 1987